These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25497672)

  • 41. Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation.
    Cerquetti L; Sampaoli C; Amendola D; Bucci B; Misiti S; Raza G; De Paula U; Marchese R; Brunetti E; Toscano V; Stigliano A
    Int J Oncol; 2010 Aug; 37(2):493-501. PubMed ID: 20596677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer.
    Schteingart DE; Sinsheimer JE; Benitez RS; Homan DF; Johnson TD; Counsell RE
    Anticancer Res; 2012 Jul; 32(7):2711-20. PubMed ID: 22753730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mitotane treatment for adrenocortical carcinoma: an overview.
    De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
    Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.
    Khan TS; Imam H; Juhlin C; Skogseid B; Gröndal S; Tibblin S; Wilander E; Oberg K; Eriksson B
    Ann Oncol; 2000 Oct; 11(10):1281-7. PubMed ID: 11106117
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases.
    Luton JP; Mahoudeau JA; Bouchard P; Thieblot P; Hautecouverture M; Simon D; Laudat MH; Touitou Y; Bricaire H
    N Engl J Med; 1979 Mar; 300(9):459-64. PubMed ID: 215912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytotoxic activity of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (mitotane) and its analogs on feminizing adrenal neoplastic cells in culture.
    Fang VS
    Cancer Res; 1979 Jan; 39(1):139-45. PubMed ID: 761184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Studies of the pharmacology of o,p'DDD in man.
    MOY RH
    J Lab Clin Med; 1961 Aug; 58():296-304. PubMed ID: 13773354
    [No Abstract]   [Full Text] [Related]  

  • 48. Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.
    Arshad U; Taubert M; Kurlbaum M; Frechen S; Herterich S; Megerle F; Hamacher S; Fassnacht M; Fuhr U; Kroiss M
    Eur J Endocrinol; 2018 Oct; 179(5):287-297. PubMed ID: 30087117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
    Theile D; Haefeli WE; Weiss J
    Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
    Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
    Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
    Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
    Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
    [No Abstract]   [Full Text] [Related]  

  • 52. Adrenal adenocarcinomas: diagnosis and management.
    Karakousis CP; Uribe J; Moore R
    J Surg Oncol; 1981; 16(4):385-9. PubMed ID: 7253657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conventional and novel strategies in the treatment of adrenocortical cancer.
    Schteingart DE
    Braz J Med Biol Res; 2000 Oct; 33(10):1197-200. PubMed ID: 11004720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
    Kerkhofs TM; Derijks LJ; Ettaieb H; den Hartigh J; Neef K; Gelderblom H; Guchelaar HJ; Haak HR
    Ther Drug Monit; 2015 Feb; 37(1):58-65. PubMed ID: 24887633
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
    Fang Z; Song R; Gong C; Zhang X; Ren G; Li J; Chen Y; Qiu L; Mei L; Zhang R; Xiang X; Chen X; Shao J
    Tumour Biol; 2016 Mar; 37(3):3515-26. PubMed ID: 26453115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis.
    Zhu CM; Lian XY; Bi YH; Hu CC; Liang YW; Li QS
    Clin Chim Acta; 2018 Oct; 485():67-73. PubMed ID: 29803896
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.
    Kroiss M; Quinkler M; Lutz WK; Allolio B; Fassnacht M
    Clin Endocrinol (Oxf); 2011 Nov; 75(5):585-91. PubMed ID: 21883349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
    Kasperlik-Zaluska AA; Cichocki A
    J Exp Ther Oncol; 2005; 5(2):125-32. PubMed ID: 16471038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p'-DDD (mitotane) in Minipigs.
    Hermansson V; Cantillana T; Hovander L; Bergman A; Ljungvall K; Magnusson U; Törneke K; Brandt I
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):267-74. PubMed ID: 17431626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
    He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
    Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.